Empagliflozin test in adults on regular dialysis
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests whether the medicine empagliflozin is safe and helpful for adults who are on regular hemodialysis and still make a small amount of urine. The goal is to see if it can improve health outcomes while tracking side effects closely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and receive maintenance hemodialysis
- You go to dialysis three times per week
- You still make some urine each day (not near zero)
- You can understand the study and sign consent
- If you can become pregnant, you must have a negative pregnancy test and use effective birth control during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether empagliflozin, a medication for heart failure, can help people who also have end-stage kidney disease and are on dialysis. It aims to see if the drug improves heart function in this group.
This trial tests whether a medicine called empagliflozin (used for diabetes and heart failure) can help people with both heart failure (with preserved pumping ability) and end-stage kidney disease who are on dialysis. The study looks at how the drug affects heart function and overall well-being.
This trial tests whether empagliflozin, a medication originally for diabetes, can help protect the remaining kidney function in people who have just started peritoneal dialysis. If you started dialysis within the last 3 months and still make some urine, this study may be a good fit.
This trial tests a medicine called empagliflozin (usually used for diabetes) to see if it can help people with very advanced kidney disease and diabetes. The study will check if this drug can slow down further kidney damage and improve overall kidney health.
This trial tests if the drug empagliflozin can improve kidney function in people hospitalized with heart failure who also develop acute kidney injury. It may help protect the kidneys while treating the heart condition.
This trial tests if empagliflozin, a diabetes medicine that also protects the kidneys, can help people who have received a kidney transplant. It may be an option if you have reduced kidney function or diabetes after transplant.
Hear when a new End Stage Renal Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.